A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine. This is an ASCO Meeting Abstract ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results